Breaking News Instant updates and real-time market news.

KINS

Kingstone Companies

$15.10

-0.25 (-1.63%)

, PRA

ProAssurance

$37.23

-0.28 (-0.75%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55

Raymond James & CFA Society of New York to hold a conference

23rd Annual Insurance Industry Conference will be held in New York on March 18-19.

KINS

Kingstone Companies

$15.10

-0.25 (-1.63%)

PRA

ProAssurance

$37.23

-0.28 (-0.75%)

CNFR

Conifer Holdings

$3.90

(0.00%)

ARGO

Argo Group

$68.09

-0.2 (-0.29%)

HALL

Hallmark Financial

$10.50

(0.00%)

EVER

EverQuote

$7.50

0.18 (2.46%)

UIHC

United Insurance

$16.45

-0.07 (-0.42%)

HIIQ

Health Insurance Innovations

$33.18

-0.99 (-2.90%)

FFG

FBL Financial

$68.04

0.135 (0.20%)

FNHC

Federated National

$17.05

0.04 (0.24%)

IHC

Independence Holding Co.

$40.00

(0.00%)

AFH

Atlas Financial

$2.51

0.19 (8.19%)

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 28

    Mar

  • 28

    Mar

  • 03

    May

  • 22

    May

  • 22

    May

  • 28

    May

KINS Kingstone Companies
$15.10

-0.25 (-1.63%)

PRA ProAssurance
$37.23

-0.28 (-0.75%)

04/04/18
RHCO
04/04/18
DOWNGRADE
RHCO
Hold
ProAssurance downgraded to Hold from Buy at SunTrust
04/04/18
RHCO
04/04/18
DOWNGRADE
Target $51
RHCO
Hold
ProAssurance downgraded to Hold at SunTrust on risk of higher losses
As reported earlier, SunTrust analyst Mark Hughes downgraded ProAssurance to Hold from Buy and lowered his price target to $51 from $55. Hughes says the company's risk of higher than expected losses is elevated while the pricing environment remains soft for ProAssurance, adding that its cyclical industry has faced "periods of sharp, unpredictable movements in frequency and severity". Moreover, the analyst see the risk of a material deviation in the earnings of ProAssurance to be greater on a peer relative basis, justifying a more cautious stance on the stock.
12/14/18
RHCO
12/14/18
NO CHANGE
Target $45
RHCO
Hold
ProAssurance price target lowered to $45 from $48 at SunTrust
SunTrust analyst Mark Hughes lowered his price target on ProAssurance to $45 and kept his Hold rating after meeting with its CEO and COO. The analyst sees the downside around the "lack of clarity on pricing and loss trends" balances the upside of "compelling valuation". Hughes adds however that he may turn more constructive on ProAssurance shares as the management navigates the "emerging cycle" and resolves its "ambiguous situation".
CNFR Conifer Holdings
$3.90

(0.00%)

05/10/18
BOSC
05/10/18
UPGRADE
BOSC
Outperform
Conifer Holdings upgraded to Outperform from Neutral at Boenning & Scattergood
07/12/18
RAJA
07/12/18
DOWNGRADE
RAJA
Market Perform
Conifer Holdings downgraded to Market Perform from Outperform at Raymond James
ARGO Argo Group
$68.09

-0.2 (-0.29%)

10/02/18
BOSC
10/02/18
INITIATION
Target $72
BOSC
Outperform
Argo Group initiated with an Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Robert Farnam initiated Argo Group Argo Group with an Outperform and $72 price target. Farnam said Argo has a good track record of growth/profitability and continues to enhance its operations via investments in technology and people. He expects underwriting performance to benefit from these investments and for a near-term improvement in net investment income due to higher interest rates.
01/15/19
COMP
01/15/19
INITIATION
Target $70
COMP
Neutral
Argo Group initiated with a Neutral at Compass Point
Compass Point analyst Bijan Moazami initiated Argo Group with a Neutral and $70 price target citing its high expense ratio combined with low leverage, which impacts ROE.
12/13/18
12/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) assumed with a Neutral from Buy at UBS with analyst Sean King saying he sees "moving parts" but says this is "not a new Coke." 2. FireEye (FEYE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Melissa Franchi citing the stock's recent relative outperformance with the shares up 20% in the past three months versus the average software name being down 9%. 3. Sabre (SABR) downgraded to Hold from Buy at Deutsche Bank with analyst Ashish Sabadra saying he expects the company's global distribution system growth to moderate in 2019. 4. Weatherford (WFT) downgraded to Underperform from Market Perform at Raymond James with analyst J. Marshall Adkins saying he expects Weatherford's upcoming maturity "wall" to push into restructuring and result in an extreme cost to the company's restructured interest payments. 5. Argo Group (ARGO) downgraded to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
KBWI
12/13/18
DOWNGRADE
KBWI
Market Perform
Argo Group downgraded to Market Perform from Outperform at Keefe Bruyette
HALL Hallmark Financial
$10.50

(0.00%)

07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/18
RAJA
07/12/18
UPGRADE
RAJA
Outperform
Hallmark Financial upgraded to Outperform from Market Perform at Raymond James
EVER EverQuote
$7.50

0.18 (2.46%)

02/26/19
OPCO
02/26/19
NO CHANGE
Target $11
OPCO
Outperform
EverQuote price target lowered to $11 from $16 at Oppenheimer
Oppenheimer analyst Jed Kelly lowered his price target for EverQuote to $11 from $16 following quarterly results, which suggest Q4 traffic headwinds were company specific. The analyst reiterates an Outperform rating on the shares as he is more encouraged toward the company's long-term outlook after it guided 2019 revenue above the Street on more balanced growth between pricing and volume, that implies Q4 marketing initiatives are re-accelerating profitable traffic.
02/26/19
ADAM
02/26/19
NO CHANGE
Target $12
ADAM
Buy
EverQuote Q4 results showed trends stabilizing, says Canaccord
Canaccord analyst Michael Graham said the Q4 results for EverQuote showed encouraging signs of stabilization. He noted revenue growth was driven by a balance of volume and revenue per quote request. He is now looking ahead to positive milestones, including the launch of renters and commercial verticals and the roll-out of EverDrive to over 20 more states. Graham reiterated his Buy rating and lowered his price target to $12 from $14 on EverQuote shares.
02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
BOFA
02/26/19
UPGRADE
Target $10.5
BOFA
Buy
EverQuote upgraded to Buy following Q4 beat at BofA/Merrill
As previously reported, BofA/Merrill upgraded EverQuote to Buy from Neutral with a new $10.50 price target following the Q4 beat. Analyst Nat Schindler said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive.
UIHC United Insurance
$16.45

-0.07 (-0.42%)

05/14/18
RAJA
05/14/18
DOWNGRADE
RAJA
Outperform
United Insurance downgraded to Outperform from Strong Buy at Raymond James
11/05/18
KBWI
11/05/18
DOWNGRADE
Target $18
KBWI
Market Perform
United Insurance downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell downgraded United Insurance Holdings to Market Perform and lowered his price target for the shares to $18 from $23. The analyst cites valuation for the downgrade.
HIIQ Health Insurance Innovations
$33.18

-0.99 (-2.90%)

03/14/19
ADAM
03/14/19
NO CHANGE
Target $62
ADAM
Buy
Health Insurance Innovations weakness provides buying opportunity, says Canaccord
Canaccord analyst Richard Close believes the weakness in shares of Health Insurance Innovations from news of an Energy and Commerce Committee's "investigation" provides a buying opportunity. Health Insurance Innovations has focused intently in recent years on improving the quality of plans offered on its platform and the compliance to best practices by which those products are sold, he notes, adding that the Trump Administration has made an effort to provide consumers greater options and choice for health insurance, and short-term medical insurance is an effective option. The analyst does not expect the Administration backing down from its position, and expects the rule changes to remain in place. Close reiterates a Buy rating and $62 price target on the shares.
03/14/19
CANT
03/14/19
NO CHANGE
CANT
Cantor says Health Insurance, eHealth concerns over House probe overblown
The House Committee on Energy & Commerce announced yesterday that they have requested information and documents from 12 distributors of short-term, limited duration insurance plans. The E&C Committee believes the companies selling these products discriminate against individuals with pre-existing conditions and mislead consumers about the nature of the coverage they are purchasing, Cantor Fitzgerald analyst Steven Halper tells investors in a research note. He points out that shares of Health Insurance Innovations (HIIQ) and eHealth (EHTH) traded sharply lower on the news. Health Insurance Innovations focuses mostly on short-term plans, while eHealth's exposure is quite small, says Halper. The analyst, however, believes concerns regarding the request for information are overblown, as any proposed legislative action would likely not pass the Senate and would almost certainly be vetoed by President Trump. Further, he reminds investors that Health Insurance Innovations recently closed out a 43-state review with virtually no impact on its businesses. He reiterates Overweight ratings on both stocks.
03/13/19
RAJA
03/13/19
NO CHANGE
RAJA
Outperform
Health Insurance Innovations selloff 'an irrational overreaction,' says Raymond James
Raymond James analyst C. Gregory Peters notes that Health Insurance Innovations' shares are under pressure on news of a new investigation by House Democrats into the short-term/limited-duration health insurance market, which should "not come as a surprise." The analyst notes that the products sold by the company are regulated at the state level and it just recently resolved a major multistate market conduct examination that did not identify any issues. Overall, Peters views the selloff in the stock as an "irrational overreaction" with zero fundamental basis. He reiterates an Outperform rating on the shares.
03/18/19
RILY
03/18/19
UPGRADE
Target $45
RILY
Buy
Health Insurance Innovations upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Randy Binner upgraded Health Insurance Innovations to Buy from Neutral with an unchanged price target of $45. The analyst cites the recent pullback in the shares as well as the company's growth outlook for the upgrade to Buy. He sees an attractive valuation at current stock levels.
FFG FBL Financial
$68.04

0.135 (0.20%)

FNHC Federated National
$17.05

0.04 (0.24%)

05/14/18
RAJA
05/14/18
UPGRADE
RAJA
Strong Buy
Federated National upgraded to Strong Buy from Outperform at Raymond James
IHC Independence Holding Co.
$40.00

(0.00%)

AFH Atlas Financial
$2.51

0.19 (8.19%)

08/07/18
BOSC
08/07/18
UPGRADE
BOSC
Outperform
Atlas Financial upgraded to Outperform from Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Robert Farnam upgraded Atlas Financial to Outperform with a $10 price target following the Q2 report. Farnam said Atlas is moving in the right direction as management works to rebuild investor trust following the Q4 2017 reserve charge and notes it does not believe the A.M. Best downgrade will have a material impact on the quality or quantity of the business. The analyst views risk/reward as compelling given share underperformance saying upside outweighs downside.

TODAY'S FREE FLY STORIES

RAVE

Rave Restaurant

$2.58

(0.00%)

07:32
10/21/19
10/21
07:32
10/21/19
07:32
Hot Stocks
Rave Restaurant appoints Brandon Solano as CEO »

Rave Restaurant has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LII

Lennox

$253.21

2.38 (0.95%)

07:32
10/21/19
10/21
07:32
10/21/19
07:32
Earnings
Lennox cuts FY19 adjusted EPS view to $11.15-$11.45 from $11.30-$11.90 »

FY19 consensus $11.41.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

IPHS

Innophos Holdings

$35.36

-0.06 (-0.17%)

07:31
10/21/19
10/21
07:31
10/21/19
07:31
Hot Stocks
Breaking Hot Stocks news story on Innophos Holdings »

Innophos Holdings agrees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$253.21

2.38 (0.95%)

07:30
10/21/19
10/21
07:30
10/21/19
07:30
Earnings
Lennox reports Q3 adjusted EPS $3.34, consensus $3.41 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

NIO

NIO Inc.

$1.52

0.055 (3.75%)

, X

U.S. Steel

$10.72

0.1 (0.94%)

07:30
10/21/19
10/21
07:30
10/21/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

NIO

NIO Inc.

$1.52

0.055 (3.75%)

X

U.S. Steel

$10.72

0.1 (0.94%)

ECA

Encana

$4.08

-0.155 (-3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 01

    Nov

BMCH

BMC Stock Holdings

$28.44

0.36 (1.28%)

07:26
10/21/19
10/21
07:26
10/21/19
07:26
Recommendations
BMC Stock Holdings analyst commentary  »

BMC Stock Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

IPHS

Innophos Holdings

$35.36

-0.06 (-0.17%)

07:26
10/21/19
10/21
07:26
10/21/19
07:26
Hot Stocks
Breaking Hot Stocks news story on Innophos Holdings »

Innophos Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$60.17

-6.4 (-9.61%)

07:26
10/21/19
10/21
07:26
10/21/19
07:26
Downgrade
Sensient rating change  »

Seaport Global downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$29.29

0.64 (2.23%)

07:25
10/21/19
10/21
07:25
10/21/19
07:25
Upgrade
PBF Energy rating change  »

PBF Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CG

Carlyle Group

$26.99

-0.14 (-0.52%)

07:22
10/21/19
10/21
07:22
10/21/19
07:22
Hot Stocks
United Road acquires Team Drive-Away from CID Capital, terms not disclosed »

United Road, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 31

    Oct

PTON

Peloton

$23.44

-0.41 (-1.72%)

07:21
10/21/19
10/21
07:21
10/21/19
07:21
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$64.47

-2.25 (-3.37%)

07:21
10/21/19
10/21
07:21
10/21/19
07:21
Downgrade
EOG Resources rating change  »

EOG Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LOAN

Manhattan Bridge Capital

$6.37

0.02 (0.31%)

07:20
10/21/19
10/21
07:20
10/21/19
07:20
Earnings
Manhattan Bridge Capital reports Q3 EPS 12c, one est. 11c »

1Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$61.05

0.64 (1.06%)

07:20
10/21/19
10/21
07:20
10/21/19
07:20
Periodicals
Verizon seeking buyer for HuffPost website, FT reports »

Verizon is seeking a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 19

    Nov

  • 09

    Dec

URGN

UroGen Pharma

$22.34

0.06 (0.27%)

07:20
10/21/19
10/21
07:20
10/21/19
07:20
Recommendations
UroGen Pharma analyst commentary  »

UroGen Pharma recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
10/21/19
10/21
07:20
10/21/19
07:20
General news
Treasury Market Outlook: yields are modestly higher as stocks rally »

Treasury Market Outlook:…

VLRX

Valeritas

$1.33

(0.00%)

07:18
10/21/19
10/21
07:18
10/21/19
07:18
Hot Stocks
Valeritas reports results from study on infusion of GLP-1 analogue with h-Patch »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.16

-0.08 (-2.47%)

07:17
10/21/19
10/21
07:17
10/21/19
07:17
Recommendations
Foamix analyst commentary  »

Foamix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

07:17
10/21/19
10/21
07:17
10/21/19
07:17
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MNTA

Momenta

$14.43

0.3 (2.12%)

07:17
10/21/19
10/21
07:17
10/21/19
07:17
Conference/Events
Momenta management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 31

    Oct

  • 07

    Dec

HSIC

Henry Schein

$62.79

-0.72 (-1.13%)

07:16
10/21/19
10/21
07:16
10/21/19
07:16
Hot Stocks
Henry Schein to be dismissed from Summit County opioid litigation »

Henry Schein announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

MYGN

Myriad Genetics

$30.56

0.24 (0.79%)

07:16
10/21/19
10/21
07:16
10/21/19
07:16
Hot Stocks
Myriad Genetics appoints Mark Pollack as CMO of Myriad Neuroscience »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

ATGE

Adtalem Global Education

$35.89

-0.37 (-1.02%)

07:16
10/21/19
10/21
07:16
10/21/19
07:16
Hot Stocks
Adtalem Global Education to sell Adtalem Educacional do Brasil to YDUQS »

Adtalem Global Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

NVR

NVR

$3,890.80

121.94 (3.24%)

07:16
10/21/19
10/21
07:16
10/21/19
07:16
Recommendations
NVR analyst commentary  »

NVR price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$64.47

-2.25 (-3.37%)

07:15
10/21/19
10/21
07:15
10/21/19
07:15
Downgrade
EOG Resources rating change  »

EOG Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.